All Actym Therapeutics articles
-
NewsEngineered bacterial therapy activates immune response in cancer preclinical studies
Researchers have developed a new bacterial immunotherapy that delivers immune-activating proteins directly to solid tumors, which can often suppress the immune system. ACTM-838 targets phagocytic immune cells within the tumor microenvironment.